Quinelorane
Quinelorane Structure.svg
Identifiers
  • (5aR,9aR)-6-propyl-5a,7,8,9,9a,10-hexahydro-5H-pyrido[2,3-g]quinazolin-2-amine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H22N4
Molar mass246.358 g·mol−1
3D model (JSmol)
  • CCCN1CCC[C@H]2[C@H]1CC3=CN=C(N=C3C2)N
  • InChI=1S/C14H22N4/c1-2-5-18-6-3-4-10-7-12-11(8-13(10)18)9-16-14(15)17-12/h9-10,13H,2-8H2,1H3,(H2,15,16,17)/t10-,13-/m1/s1 ☒N
  • Key:TUFADSGTJUOBEH-ZWNOBZJWSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Quinelorane is a drug which acts as a dopamine agonist for the D2[1][2][3] and D3 receptor.

See also

References

  1. ^ Caine SB, Negus SS, Mello NK, Patel S, Bristow L, Kulagowski J, Vallone D, Saiardi A, Borrelli E (April 2002). "Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists". Journal of Neuroscience. 22 (7): 2977–88. doi:10.1523/JNEUROSCI.22-07-02977.2002. PMC 6758322. PMID 11923462.
  2. ^ Gasior M, Paronis CA, Bergman J (January 2004). "Modification by dopaminergic drugs of choice behavior under concurrent schedules of intravenous saline and food delivery in monkeys". The Journal of Pharmacology and Experimental Therapeutics. 308 (1): 249–59. doi:10.1124/jpet.103.052795. PMID 14563783.
  3. ^ Brooks JM, Sarter M, Bruno JP (September 2007). "D2-like receptors in nucleus accumbens negatively modulate acetylcholine release in prefrontal cortex". Neuropharmacology. 53 (3): 455–63. doi:10.1016/j.neuropharm.2007.06.006. PMC 2000917. PMID 17681559.